ReviewAdvances in therapy2026
Understanding Patient Preferences on Inflammatory Bowel Disease Treatment Modalities and Outcomes: A Global Targeted Literature Review.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInflammatory bowel diseases (IBDs) are chronic diseases, including Crohn's disease (CD) and ulcerative colitis (UC). Given the heterogeneity in disease presentation, treatment responses, and lifestyle impacts associated with IBD, understanding patient preferences is essential to inform patient-centered care. By identifying how patients prioritize different aspects of treatment, physicians can provide more personalized, effective management of IBD.
methodsA global targeted literature review search was conducted in MEDLINE and Embase between January 1, 2004 and July 30, 2024, supplemented by conference abstracts to explore patient preferences on treatment modalities and treatment outcomes in IBD.
resultsSixty-two studies were identified that matched inclusion criteria. Across studies, it was identified that patients primarily base their treatment decisions on a hierarchy of three factors: efficacy, safety, and ease of administration. Treatment efficacy was often attributed higher importance than safety/tolerability, with factors "time to response" and "improvement in quality of life (QoL)" ranked highly for consideration by patients. Variations in symptom priorities were noted between patients with UC and CD, with patients with UC prioritizing diarrhea reduction while those with CD focusing on abdominal pain relief. Treatment preferences were influenced by route of administration and the ability to self-administer treatments, illustrating the diversity of patient preferences in IBD. Preference for subcutaneous (SC) over intravenous (IV) administration was noted; however, this preference was often dependent on other factors including dosing frequency, ease of use, and previous treatment experiences.
conclusionPatient treatment preferences in IBD represent a trade-off between many factors. However, preferences are highly individualized based on patient experience; as such, there is a need to promote shared decision-making between patients and physicians. To support this, patients should be equipped with the necessary resources to facilitate informed decision-making and active involvement in discussions with their healthcare providers, ensuring that treatment plans align with their personal values and preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.